Tech Company Financing Transactions
Detechgene Funding Round
On 8/27/2025, Detechgene announced $3.7 million in Seed funding from Campus Fund and NRW.BANK.
Transaction Overview
Company Name
Announced On
8/27/2025
Transaction Type
Venture Equity
Amount
$3,700,000
Round
Seed
Investors
Proceeds Purpose
This funding advances its mission to make molecular diagnostics fast and mobile. The fresh capital will commercialise the platform and ramp up production.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Nattermannallee 1
Cologne, 50829
Germany
Cologne, 50829
Germany
Phone
Undisclosed
Website
Email Address
Overview
Detechgene GmbH was founded in 2022 by Dr. Reza Esmaillie and Dr. Robin Bayer and is a Life-Science Bio-Tech Company in the heart of Cologne. At the heart of Detechgene's mission is the development of a cutting-edge rapid test procedure, which combines the precision of a PCR with the ease of use of a rapid antigen test. This versatile technology platform is designed to detect a wide array of viral, bacterial, and fungal pathogens, making it an invaluable tool in the fight against infectious diseases in various branches. Through our innovative approach, we aim to revolutionize diagnostics and significantly enhance healthcare outcomes worldwide.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Robin Bayer
Chief Executive Officer
Reza Esmaillie
Browse more venture capital transactions:
Prev: 8/27/2025: Leal Therapeutics venture capital transaction
Next: 8/27/2025: Vercel venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs